Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.57 |
| ▸ | GCK | P35557 | 1/20 | 0.56 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.55 |
| ▸ | FEN1 | P39748 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11510357 | 0.87 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2LMNAHDAC8AKR1C3 | |
| SCHEMBL11662847 | 0.86 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2LMNAHDAC8PKM | |
| SCHEMBL257929 | 0.86 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2LMNAHDAC8AKR1C3 | |
| SCHEMBL8738919 | 0.85 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2LMNAERCC5FEN1 | |
| SCHEMBL11510994 | 0.84 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2LMNAHDAC8AKR1C3 | |
| SCHEMBL30098882 | 0.83 | TAS1R3 (0.68) | ALDH1A1SMN1; SMN2NPC1NPSR1GPR139 | |
| SCHEMBL8387420 | 0.83 | MEN1 (0.59) | ALDH1A1SMN1; SMN2LMNANPC1KAT6A | |
| SCHEMBL7053844 | 0.83 | HDAC8 (0.73) | ALDH1A1SMN1; SMN2LMNAHDAC8AKR1C3 | |
| SCHEMBL381132 | 0.83 | TAS1R3 (0.68) | ALDH1A1SMN1; SMN2NPC1NPSR1GPR139 | |
| SCHEMBL8593124 | 0.82 | NPSR1 (0.69) | ALDH1A1SMN1; SMN2LMNAHDAC8NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009914-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-13 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7504431-B2 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL- MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | CACNA1F, CACNA1A, CACNA1D | ALDH1A1 1848/4885SMN1; SMN2 2190/4885LMNA 535/4885 |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | ALDH1A1 1635/4885SMN1; SMN2 2264/4885LMNA 4174/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | ALDH1A1 1929/4885SMN1; SMN2 1840/4885LMNA 1962/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | ALDH1A1 1744/4885SMN1; SMN2 1569/4885LMNA 2969/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | ALDH1A1 1929/4885SMN1; SMN2 1840/4885LMNA 1962/4885 |
| US-20220009914-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | ATF4, ATF1, FBL | ALDH1A1 2865/4885SMN1; SMN2 3306/4885LMNA 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.